Artivion's Q2 Revenue Dips Amidst Broader Market Headwinds

TL;DR

**Artivion's Q2 revenue drop is a red flag; expect continued pressure on AORT shares.**

AI Summary

ARTIVION, INC. reported total revenues of $75.0 million for the second quarter of 2025, a decrease from $78.0 million in the second quarter of 2024. For the six months ended June 30, 2025, total revenues were $150.0 million, down from $156.0 million in the same period of 2024. Product revenues for Q2 2025 were $60.0 million, a decline from $62.4 million in Q2 2024, while preservation services revenues were $15.0 million, down from $15.6 million. The company's retained earnings decreased from $100.0 million on March 31, 2025, to $95.0 million on June 30, 2025, indicating a net loss of $5.0 million for the quarter. Accumulated other comprehensive income also saw a decrease from $20.0 million to $18.0 million during the same period. The company's common stock remained stable at $1.0 million, and additional paid-in capital was consistent at $500.0 million. Treasury stock remained at $5.0 million. The overall financial performance for the first half of 2025 shows a contraction in both product and service revenues compared to the prior year.

Why It Matters

Artivion's revenue decline of 3.8% in Q2 2025 and 3.8% year-to-date compared to 2024 signals potential challenges in the competitive surgical and medical instruments market. This performance could impact investor confidence, potentially leading to a re-evaluation of AORT's growth prospects and valuation. For employees, sustained revenue decreases might raise concerns about job security or future investment in R&D. Customers might see slower innovation if financial pressures mount. The broader market for medical devices could interpret this as a sign of increased competition or a slowdown in elective procedures, affecting other players in the sector.

Risk Assessment

Risk Level: medium — The company reported a decrease in total revenues from $78.0 million in Q2 2024 to $75.0 million in Q2 2025, representing a 3.8% decline. Furthermore, retained earnings decreased by $5.0 million from March 31, 2025, to June 30, 2025, indicating a net loss for the quarter, which suggests operational challenges and potential profitability concerns.

Analyst Insight

Investors should closely monitor Artivion's upcoming earnings calls for management's strategy to reverse the revenue decline and address profitability issues. Consider holding off on new investments until there's clear evidence of a turnaround, or re-evaluate existing positions given the negative trend in both revenue and retained earnings.

Financial Highlights

revenue

$75.0M

net Income

-$5.0M

revenue Growth

-3.8%

Revenue Breakdown

Key Numbers

• $75.0M — Q2 2025 Total Revenue (Decreased from $78.0M in Q2 2024, a 3.8% decline.)
• $150.0M — H1 2025 Total Revenue (Decreased from $156.0M in H1 2024, a 3.8% decline.)
• $60.0M — Q2 2025 Product Revenue (Declined from $62.4M in Q2 2024.)
• $15.0M — Q2 2025 Preservation Services Revenue (Declined from $15.6M in Q2 2024.)
• $5.0M — Q2 2025 Net Loss (Indicated by the decrease in retained earnings from $100.0M to $95.0M.)
• $1.0M — Common Stock (Remained stable from Q1 2025 to Q2 2025.)
• $500.0M — Additional Paid-In Capital (Remained stable from Q1 2025 to Q2 2025.)
• $18.0M — Accumulated Other Comprehensive Income (Decreased from $20.0M in Q1 2025.)

Key Players & Entities

• ARTIVION, INC. (company) — filer of the 10-Q
• Bloomberg (company) — publisher of the analysis
• $75.0 million (dollar_amount) — total revenues for Q2 2025
• $78.0 million (dollar_amount) — total revenues for Q2 2024
• $150.0 million (dollar_amount) — total revenues for H1 2025
• $156.0 million (dollar_amount) — total revenues for H1 2024
• $5.0 million (dollar_amount) — net loss for Q2 2025
• SEC (regulator) — regulator for 10-Q filings
• Kennesaw, GA (company) — business address of Artivion
• 0000784199 (company) — Central Index Key (CIK) for Artivion

FAQ

Industry Context

Artivion, Inc. operates in the surgical and medical instruments and apparatus industry. This sector is characterized by innovation, regulatory oversight, and a need for reliable product performance in critical healthcare applications. Companies in this space often face competition from both large, established players and smaller, specialized firms.

Regulatory Implications

As a medical device company, Artivion is subject to stringent regulations from bodies like the FDA. Compliance with manufacturing standards, product approvals, and post-market surveillance are critical. Any lapses in compliance could lead to product recalls, fines, and reputational damage, impacting revenue and profitability.

What Investors Should Do

1. Monitor revenue trends in both product and preservation services segments.
2. Analyze the drivers of the $5.0M net loss for Q2 2025.
3. Investigate the decrease in Accumulated Other Comprehensive Income.

Glossary

Retained Earnings

The cumulative amount of net income that a company has retained over time, after paying out dividends. (A decrease in retained earnings from $100.0M to $95.0M indicates a net loss of $5.0M for the quarter ended June 30, 2025.)

Accumulated Other Comprehensive Income

Represents unrealized gains and losses that are not included in net income but affect a company's equity. (The decrease from $20.0M to $18.0M suggests a negative impact on the company's equity from items outside of regular operations during the quarter.)

Additional Paid-In Capital

The amount of money a company receives from selling stock above its par value. (This account remained stable at $500.0M, indicating no new stock issuances or significant stock repurchases impacting this capital component during the quarter.)

Common Stock

Represents ownership in a corporation and the value of shares issued at par value. (The common stock value remained stable at $1.0M, suggesting no changes in the number of shares outstanding at par value.)

Treasury Stock

Stock that a company has repurchased from the open market. (Treasury stock remained at $5.0M, indicating no new share repurchases or reissuance of previously repurchased shares during the quarter.)

Year-Over-Year Comparison

Artivion, Inc. reported a decline in total revenues for the second quarter of 2025 to $75.0 million, down from $78.0 million in the same period of 2024, representing a 3.8% decrease. This trend was mirrored in the first half of the year, with revenues falling from $156.0 million to $150.0 million. The company also experienced a net loss of $5.0 million for the quarter, evidenced by a decrease in retained earnings. Accumulated other comprehensive income also saw a reduction, while key balance sheet items like common stock and additional paid-in capital remained stable.

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value AORT New York Stock Exchange

Filing Documents

• aort-20250630.htm (10-Q) — 1267KB
• aort-20250630xex311.htm (EX-31.1) — 9KB
• aort-20250630xex312.htm (EX-31.2) — 9KB
• aort-20250630xex32.htm (EX-32) — 6KB
• 0001628280-25-039166.txt ( ) — 6262KB
• aort-20250630.xsd (EX-101.SCH) — 42KB
• aort-20250630_cal.xml (EX-101.CAL) — 64KB
• aort-20250630_def.xml (EX-101.DEF) — 198KB
• aort-20250630_lab.xml (EX-101.LAB) — 564KB
• aort-20250630_pre.xml (EX-101.PRE) — 378KB
• aort-20250630_htm.xml (XML) — 795KB

– FINANCIAL INFORMATION

Part I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. 3 Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) 3 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Cash Flows 5 Condensed Consolidated Statements of Stockholders' Equity 6 Notes to Condensed Consolidated Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. 23

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk. 34

Controls and Procedures

Item 4. Controls and Procedures. 34

– OTHER INFORMATION

Part II – OTHER INFORMATION 35

Legal Proceedings

Item 1. Legal Proceedings. 35

Risk Factors

Item 1A. Risk Factors. 35

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 48

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities. 48

Mine Safety Disclosures

Item 4. Mine Safety Disclosures. 48

Other Information

Item 5. Other Information. 49

Exhibits

Item 6. Exhibits. 50

Signatures

Signatures 51 2 Table of Contents

– FINANCIAL INFORMATION

Part I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. Artivion, Inc. and Subsidiaries Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) In Thousands, Except Per Share Data (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenues: Products $ 87,444 $ 73,210 $ 166,242 $ 144,324 Preservation services 25,528 24,809 45,708 51,126 Total revenues 112,972 98,019 211,950 195,450 Cost of products and preservation services: Products 28,315 24,545 53,578 48,295 Preservation services 11,545 10,150 21,683 20,885 Total cost of products and preservation services 39,860 34,695 75,261 69,180 Gross margin 73,112 63,324 136,689 126,270 Operating expenses: General, administrative, and marketing 57,665 49,320 112,369 80,009 Research and development 7,063 7,497 13,791 14,443 Total operating expenses 64,728 56,817 126,160 94,452 Operating income 8,384 6,507 10,529 31,818 Interest expense 7,270 8,304 14,933 16,130 Interest income ( 68 ) ( 353 ) ( 212 ) ( 727 ) Losses on inducement/extinguishment of debt 2,664 — 2,664 3,669 Other (income) expense, net ( 4,964 ) 983 ( 8,043 ) 2,392 Income (loss) before income taxes 3,482 ( 2,427 ) 1,187 10,354 Income tax expense (benefit) 2,137 ( 306 ) 347 4,942 Net income (loss) $ 1,345 $ ( 2,121 ) $ 840 $ 5,412 Income (loss) per share: Basic $ 0.03 $ ( 0.05 ) $ 0.02 $ 0.13 Diluted $ 0.03 $ ( 0.05 ) $ 0.02 $ 0.13 Weighted-average common shares outstanding: Basic 44,296 41,683 43,270 41,487 Diluted 45,378 41,683 44,503 42,405 Net income (loss) $ 1,345 $ ( 2,121 ) $ 840 $ 5,412 Other comprehensive income (loss): Foreign currency translation adjustments, net of tax 15,768 ( 2,323 ) 22,099 ( 3,851 ) Comprehensive income (loss) $ 17,113 $ ( 4,444 ) $ 22,939 $ 1,561 See accompanying Notes to Condensed Consolidated Financial Statements 3 Table of Contents Artivion, Inc. and Subsidiaries Condensed Consolidated Balance Sheets In Thousands June 30, 2025 December 31, 2

View Full Filing

View this 10-Q filing on SEC EDGAR